Connect with us

Business

This ASX share potentially ‘has no value from here’, says broker

Published

9 months ago

on

April 4, 2025

By

Noosa Online News Publisher

Image source: Getty Images

ASX biotech share Opthea Limited (ASX: OPT) remains frozen at 60 cents apiece following a failed Phase 3 clinical trial.

In an update this week, we learned that Opthea has decided to cease development of its sozinibercept (OPT-302) treatment.

This follows the

Click here to view the original article.

Related Topics:fool.com.au

How I position my portfolio for downside protection

ASX shares are on sale! What are you buying?

Continue Reading

Advertisement

General19 hours ago

Search underway for missing boat off South Australia’s Cape Jaffa

Noosa News20 hours ago

Queensland coroner investigates ‘extremely unusual’ deaths of premature twin boys

General22 hours ago

Reuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism

Noosa News24 hours ago

Bail applications continue to climb – Proctor

About Us	Contact Us

© 2025 Noosa Online News
Privacy Policy